鹭燕医药(002788) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥3,360,924,808.34, representing a decrease of 1.94% compared to the same period last year[7]. - Net profit attributable to shareholders was ¥51,218,000.58, an increase of 15.33% year-on-year[7]. - The net profit after deducting non-recurring gains and losses was ¥49,160,920.56, reflecting a year-on-year growth of 12.68%[7]. - Basic and diluted earnings per share were both ¥0.16, up 14.29% from the previous year[7]. - The company reported a total comprehensive income of CNY 49,895,800.78 for Q1 2020, an increase from CNY 44,218,057.67 in the previous year[41]. - The net profit for the first quarter of 2020 was CNY 5,316,133.00, compared to CNY 3,548,283.75 in the same period last year, representing a significant increase[44]. - Operating profit decreased to CNY 2,985,427.28 from CNY 4,948,545.00 year-over-year[44]. Cash Flow - The net cash flow from operating activities improved to -¥374,020,009.96, a 41.67% increase compared to the previous year[7]. - Cash inflow from operating activities totaled CNY 3,671,739,573.99, an increase from CNY 3,558,103,932.73 in the previous year[47]. - The net cash flow from operating activities was negative at CNY -374,020,009.96, improving from CNY -641,202,280.14 year-over-year[48]. - The company reported a decrease in cash outflow from operating activities, totaling CNY 4,211,201,487.83, compared to CNY 3,765,749,858.32 in the previous year[51]. - The company received CNY 3,526,970,329.39 from other operating activities, up from CNY 2,763,965,720.21 year-over-year[51]. Assets and Liabilities - Total assets at the end of the reporting period were ¥7,725,839,139.33, an increase of 2.49% from the end of the previous year[7]. - Total liabilities increased to CNY 5,787,924,599.84 from CNY 5,649,973,377.86, which is an increase of about 2.45%[32]. - The company's equity attributable to shareholders reached CNY 1,843,542,134.37, up from CNY 1,791,688,831.15, indicating a growth of approximately 2.9%[33]. - Current assets totaled CNY 6,465,291,359.34, up from CNY 6,290,725,815.62, indicating an increase of about 2.77%[30]. - The inventory balance as of March 31, 2020, was CNY 1,809,678,746.12, compared to CNY 1,758,700,452.97, reflecting an increase of about 2.3%[30]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,148[12]. - The largest shareholder, Xiamen Maidi Ken Technology Co., Ltd., held 35.34% of the shares, amounting to 115,506,840 shares[12]. Expenses - Sales expenses increased by 35.69% year-on-year, mainly due to the company's optimization of the management system and adjustments to internal management structure[16]. - Research and development expenses for Q1 2020 were CNY 867,248.30, a slight increase from CNY 818,182.33 in Q1 2019[39]. - The company’s financial expenses for Q1 2020 were CNY 43,587,763.41, up from CNY 36,070,489.34 in the same period last year[39]. Other Financial Metrics - The company reported non-operating income of ¥3,988,251.11 from government subsidies during the reporting period[9]. - The company’s deferred income tax liabilities were not reported in the current period, indicating a potential area for future financial assessment[39]. - The first quarter report was not audited, which may affect the reliability of the financial data presented[54]. - The company has not adopted the new revenue and leasing standards for the current year, indicating a potential impact on future financial reporting[53].